News StemRIM

Stocks

4599

JP3399690001

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:30:00 2026-07-24 EDT			5-day change	1st Jan Change
299.00 ^JPY	-0.33%		+1.70%	+13.69%

07-22	Stemrim Announces Patent Registration in Mexico for Redasemtide as Therapeutic Agent for Cartilage Disorders	CI
07-08	StemRIM Inc. Announces Patent Registration For Stem Cell Gene Therapy Technology SR-GT1 Aimed At Curative Treatment Of Dystrophic Epidermolysis Bullosa In South Korea	CI

All News

Mentions Relevance

07-22	Stemrim Announces Patent Registration in Mexico for Redasemtide as Therapeutic Agent for Cartilage Disorders	CI
07-08	StemRIM Inc. Announces Patent Registration For Stem Cell Gene Therapy Technology SR-GT1 Aimed At Curative Treatment Of Dystrophic Epidermolysis Bullosa In South Korea	CI
06-17	StemRIM Announces Patent Registration for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders	CI
06-16	StemRIM Inc Announces Patent Registration In Russia For Redasemtide As Therapeutic Drug For Fatty Liver And Non-Alcoholic Steatohepatitis	CI
06-16	StemRIM to Register Russian Patent of Drug Candidate for Fatty Liver Disease	MT
06-10	StemRIM Reports Earnings Results for the Nine Months Ended April 30, 2026	CI
05-12	Stemrim Inc. Announces Progress for Regeneration-Inducing Medicine Redasemtide	CI
04-15	StemRIM Finishes Enrollment in Phase 1/2 Redasemtide Study	MT
04-15	StemRIM Inc. Announces Completion of Patient Enrollment in Phase 1/2 InvestigatorInitiated Clinical Trial of Redasemtide for Patients with Ischemic Cardiomyopathy	CI
03-11	StemRIM Reports Earnings Results for the Half Year Ended January 31, 2026	CI
03-02	StemRIM Wins Patent for SR-GT1 Stem Cell Gene Therapy	MT
03-02	StemRIM Inc. Announces Patent Registration for Stem Cell Gene Therapy Technology Aimed At Curative Treatment of Dystrophic Epidermolysis Bullosa	CI
02-17	StemRIM Secures Canada Patent for Cartilage Disorder Use of Redasemtide	MT
02-17	Stemrim Inc. Announces Patent Registration for the Use of Thehmgb1 Fragment Peptide, as an Additional Therapeutic Indication of Cartilage Disorders	CI
12-24	Stemrim Inc. Announces Completion of Patient Enrollment in the Global Phase 2B Clinical Trial of the Redasemtide for Acute Ischemic Stroke	CI
12-17	StemRIM Inc. Announces Patent Registration (JP) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Fatty Liver and Non-alcoholic Steatohepatitis	CI
12-10	StemRIM Narrows Losses in Fiscal Q1	MT
12-10	StemRIM Sets Up Voluntary Compensation Committee	MT
25-10-16	StemRIM Wins Patent in Japan for Gene Therapy Targeting Rare Skin Disorder	MT
25-10-16	StemRIM Inc. Announces Patent Registration for Stem Cell Gene Therapy Technology Aimed At Curative Treatment of Dystrophic Epidermolysis Bullosa	CI
25-10-01	StemRIM Secures US Patent for Psoriasis Drug Candidate Redasemtide	MT
25-09-30	StemRIM Inc. Announces Patent Registration (US) for the Use of the HMGB1 Fragment Peptide, as an Additional Therapeutic Indication for Psoriasis	CI
25-09-21	StemRIM(TSE:4599) dropped from S&P Global BMI Index	CI
25-09-18	StemRIM Proposes Stock Options for Executives, Employees and Collaborators	MT
25-07-21	StemRIM Completes Patient Enrollment for Phase 2 Trial of Orphan Drug Redasemtide in Epidermolysis Bullosa	MT